[{"orgOrder":0,"company":"Themis Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Themis Gets Drug Controller\u2019s Nod to Launch Inosine Pranobex a Novel Medicine to Treat Covid19, A Viral Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Themis Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DCGI Approved Themis Medicare\u2019s Viralex Effective Against Covid-19, Viral Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Inosine Pranobex
VIRALEX (inosine pranobex) is an immunomodulatory agent with antiviral activity across a broad spectrum. It boosts the body’s defenses against viral infections by enhancing both innate and adaptive immunity.
Approval for VIRALEX® (Inosine pranobex) is based on the results of Phase 3 trial demonstrated, 80.17% of patients treated with VIRALEX® showed clinical improvement on day 6, which is significantly higher (p<0.001) from that in the controlled group.